(7 years ago)
Lords ChamberMy Lords, the Foreign Secretary and the Minister for Africa are engaging with the region and other international partners, especially South Africa and the African Union, the EU and the UN. In fact, my honourable friend the Minister for Africa is in Harare at this moment with the aim of engaging with leading figures from all parts of the political spectrum in Zimbabwe.
My Lords, with the likelihood that President-elect Mnangagwa will form a Government of national unity in Zimbabwe, one of his key focuses will be on resurrecting the agricultural sector and job creation. What support can our Government give, whether bilaterally or through multilateral agencies, to revive the agricultural sector, possibly providing compensation to former landowners in Zimbabwe?
My Lords, DfID is already active on a number of fronts in Zimbabwe, as the noble Lord will be aware. If there are free and fair elections, Britain and indeed the international community would be prepared to support the country in whatever way is thought appropriate. We are putting together a package of support that will be tied to political and economic reform and implemented alongside international partners.
(11 years, 9 months ago)
Lords ChamberMy Lords, when the arrangements for the cancer drugs fund pass to the NHS Commissioning Board in April, there will be standard operating procedures for the fund, which will provide greater consistency of access across the country while also preserving the right of clinicians to request any drug that they think will help a patient. The standard operating procedures will be published very shortly, and the noble Lord will then receive a fuller answer to his question.
My Lords, can the Minister elaborate on what reports, if any, have been produced from the Chemotherapy Intelligence Unit in Oxford on the efficacy of the cancer drugs fund? What will be done for those patients who have received relief from this fund for their treatment in future?
My Lords, the noble Lord raises a very important point because clinical audit of the drugs in the cancer drugs fund and their use will be extremely important in informing the use of these drugs going forward and, indeed, in determining their price under a value-based pricing scheme. As yet we have not heard from the Oxford Cancer Intelligence Unit although I understand that we will receive a preliminary report quite soon. However, as I mentioned earlier, when the current fund comes to an end we will ensure that those patients who are receiving drugs under it will continue to do so.